Moderna (MRNA) says Omicron-targeted COVID shot shows better response

Be the First to Comment Read

Moderna (MRNA) says Omicron-targeted COVID shot shows better response

Follow us on Google News:
 Moderna (MRNA) says Omicron-targeted COVID shot shows better response
Image source: © Pcruciatti | Megapixl.com

Highlights:
  • Moderna’s upgraded version of its coronavirus vaccine produced a better immune response as a booster dose against the Omicron variant.
  • The vaccine, which was given as a fourth dose in a trial that enrolled more than 800 people.
  • The booster, mRNA-1273.214, raised virus-neutralizing antibodies by eight-fold against Omicron.

Moderna Inc said on Wednesday a new version of its coronavirus vaccine produced a better immune response against Omicron than the original shot, as the drugmaker pursues a booster against a surge in infections in the fall season.

The vaccine, which was given as a fourth dose in a trial that enrolled more than 800 people, raised virus-neutralizing antibodies by eight-fold against Omicron.

Also Read: MCK to ABC: 5 healthcare stocks that returned strong 1-year, YTD gains

The company said it plans to submit data on the vaccine, which targets Omicron as well as the original coronavirus strain, to regulators in the coming weeks and the doses could be available to consumers in late summer, sending its shares up 3%.

Moderna president Stephen Hoge said the company was in touch with the U.S. Food and Drug Administration (FDA) and other regulators on the design of the study, which should make the filings a smooth process.

Moderna's new vaccine showed better results against Omicron variant

"We expect those to be relatively straightforward discussions and submissions," he said.

It is not known if countries including the United States will adopt annual fall boosters, similar to the flu market.

"The data look quite comforting and convincing," said Dr. William Schaffner, an infectious disease expert at Vanderbilt University Medical Center.

Also Read: AAPL to ADBE: Should you consider these 5 tech stocks amid inflation?

He said while he expects the FDA to authorize the vaccine, it is not known if the U.S. Centers for Disease Control and Prevention will recommend the shot for all adults or for a subset of the population such as older people.

Chief Executive Stephane Bancel said the company had been ramping up manufacturing of the new booster with an aim to be ready to ship as early as August.

Also Read: Facebook parent drops FB symbol, to trade under META ticker from June 9

In the study, which did not measure vaccine effectiveness, the booster, the vaccine generated greater antibodies against the Alpha, Beta, Gamma, Delta variants compared to the original shot.

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Featured Articles